A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 WHO Classification: Characterization of 554 Consecutive Tumors with Emphasis on BRAF-Negative Cases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37307878/
Most studies for comprehensive molecular profiling of papillary thyroid carcinoma (PTC) have been performed before the 2017 WHO classification, in which the diagnostic criteria of follicular variant of PTC have...
Conclusions/Relevance: Driver gene fusions were identified in 8.5% of PTCs and were clinically relevant given the emerging targeted kinase inhibitor therapy. Of the 1.6% of cases for which no driver alteration was detected, the specificity of drivers tested and tumor classification require further investigation.
Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37315261/
Selpercatinib demonstrated clinically meaningful and durable intracranial activity in Chinese patients with brain metastases from RET -altered NSCLC, consistent with the global LIBRETTO-001 trial.
Conclusion: Selpercatinib demonstrated clinically meaningful and durable intracranial activity in Chinese patients with brain metastases from RET-altered NSCLC, consistent with the global LIBRETTO-001 trial.
Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37282666/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
Source : https://www.frontiersin.org/articles/10.3389/fonc.2023.1178313/full
The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug's approval...
Conclusions/Relevance: The activity of prospective preoperative selpercatinib in this case establishes proof of concept of the potential utility of RET inhibitor therapy in early-stage RET fusion-positive NSCLC.
Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37278236/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: More effective and less toxic systemic treatment targeting genomic alterations is needed to improve long-term outcomes of thyroid cancer.